SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026)
| Date | 25 March 2026 |
|---|---|
| Court | CoA |
| Division | Luxembourg (LU) |
| Type of action | Withdrawal (RoP265) |
| Case number(s) | UPC_CoA_528/2024;UPC_CoA_529/2024 |
| Registry reference | UPC_CoA_528/2024 · UPC_CoA_529/2024 |
| Parties | SANOFI-AVENTIS DEUTSCHLAND GMBH, SANOFI-AVENTIS GROUPE S.A., SANOFI WINTHROP INDUSTRIE S.A., and Regeneron Pharmaceuticals Inc. v. AMGEN, INC |
Summary pending review. Official UPC registry metadata imported on 24 September 2026.
Official decision (PDF) · UPC registry entry
Case timeline
- 25 November 2025 : Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) UPC_CoA_528/2024
- 18 February 2026 : SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) UPC_CoA_528/2024 · UPC_CoA_529/2024
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
English summary awaiting review. Read the French case note.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- defendantINC5 decisions in the corpusFollow this party
- claimantSANOFI-AVENTIS DEUTSCHLAND GMBH28 decisions in the corpusFollow this party
- claimantSANOFI-AVENTIS GROUPE S.A.8 decisions in the corpusFollow this party
- claimantSANOFI WINTHROP INDUSTRIE S.A., and Regeneron Pharmaceuticals Inc.2 decisions in the corpusFollow this party
- defendantAMGEN3 decisions in the corpusFollow this party
Exact name as it appears in the record, group affiliation only where sourced and dated.
Decisions in the same proceedings and documented appeals
- 25 November 2025 Amgen v Regeneron Pharmaceuticals (CoA, 25 November 2025) Appeal RoP220.1 · UPC_CoA_529/2024
- 25 November 2025 Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) Appeal RoP220.1 · UPC_CoA_528/2024
La cour d’appel infirme l’annulation de l’EP 3 666 797 d’Amgen, juge le brevet suffisamment décrit, sans extension et inventif faute d’attente raisonnable de succès à la date de priorité, et condamne Sanofi et Regeneron aux frais des deux instances.
- 18 February 2026 SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) Generic application · UPC_CoA_528/2024, UPC_CoA_529/2024
La demande d'effet suspensif est rejetée : elle n'était pas motivée et l'arrêt attaqué, qui rejette la demande en nullité, ne modifie pas la situation du brevet et n'a rien à suspendre.
- 25 March 2026 SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026) Withdrawal (RoP265) · UPC_CoA_528/2024, UPC_CoA_529/2024
What the record states
- Nature of the act
- Withdrawal (RoP265)
- Outcome (Dhenne Avocats summary)
- La cour d’appel autorise le retrait des requêtes en révision de Sanofi et Regeneron, déclare la procédure close et refuse le remboursement des frais de justice, une seule taxe ayant été payée pour deux requêtes.
- Appeal
- Decision of the Court of Appeal.
- Instance
- Court of Appeal decision.
Patents mentioned
EP 3 666 797mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) cited in this record
- Lindal Dispenser v Rocep-Lusol (CoA, 23 December 2025) cited in this record
- Amgen v Regeneron Pharmaceuticals (CoA, 25 November 2025) cited in this record
- Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) cited in this record
- 10x Genomics v Curio Bioscience (CoA, 5 July 2024) cited in this record
Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 666 797Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) recorded proprietor: Amgen Inc | Mentioned in the analysis (role not qualified) Also mentioned in 21 other decision(s): Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) · Sanofi-Aventis Deutschland v Amgen (CFI, 16 July 2024) · Regeneron Pharmaceuticals v Amgen (CFI, 16 July 2024) · SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) · Dehns v Regeneron Pharmaceuticals (CFI, 22 October 2024) · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47230/2024, 22 October 20 · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47238/2024, 22 October 20 · Amgen v Sanofi Winthrop Industrie (CFI, 29 July 2024) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.